Filtered By:
Condition: Coronary Heart Disease
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 806 results found since Jan 2013.
Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events
CONCLUSIONS AND RELEVANCE: A protein risk score was significantly associated with ASCVD events in primary and secondary event populations. When added to clinical risk factors, the protein risk score and polygenic risk score both provided statistically significant but modest improvement in discrimination.PMID:37606673 | DOI:10.1001/jama.2023.13258
Source: Atherosclerosis - August 22, 2023 Category: Cardiology Authors: Hannes Helgason Thjodbjorg Eiriksdottir Magnus O Ulfarsson Abhishek Choudhary Sigrun H Lund Erna V Ivarsdottir Grimur Hjorleifsson Eldjarn Gudmundur Einarsson Egil Ferkingstad Kristjan H S Moore Narimon Honarpour Thomas Liu Huei Wang Thomas Hucko Marc S S Source Type: research
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases
Eur Heart J Cardiovasc Pharmacother. 2023 Aug 10:pvad059. doi: 10.1093/ehjcvp/pvad059. Online ahead of print.ABSTRACTAlthough bioinformatic methods gained a lot of attention in the latest years, their use in real-world studies for primary and secondary prevention of atherosclerotic cardiovascular diseases (ASCVD) is still lacking. Bioinformatic resources have been applied to thousands of individuals from the Framingham Heart Study as well as health care-associated biobanks such as the UK Biobank, the Million Veteran Program, and the CARDIoGRAMplusC4D Consortium and randomized controlled trials (i.e. ODYSSEY, FOURIER, ASPRE...
Source: Atherosclerosis - August 10, 2023 Category: Cardiology Authors: Giuditta Benincasa Rosa Suades Teresa Padr ò Lina Badimon Claudio Napoli Source Type: research
Discharge prescription patterns for antiplatelet and statin therapy following carotid endarterectomy: an analysis of the vascular quality initiative
Conclusions
Although statin use has substantially improved following CEA, more than half of individuals not on a statin preprocedure remained this way at discharge. In addition, DAPT at discharge was frequent, a quarter of whom were on SAPT preprocedure. Further efforts are needed to improve rates of new statin prescriptions, ensure appropriate APT intensity at discharge and determine how different discharge APT regimens impact outcomes.
Source: BMJ Open - July 25, 2023 Category: General Medicine Authors: Eppler, M., Singh, N., Ding, L., Magee, G., Garg, P. Tags: Open access, Cardiovascular medicine Source Type: research
Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort
ConclusionsThe VITAL data confirmed diabetes as an important risk factor for cardiovascular events in a contemporary cohort but did not show cardiovascular benefits of aspirin in primary prevention among people with diabetes who were shown to be at higher risk of cardiovascular events.
Source: Journal of Endocrinological Investigation - June 15, 2023 Category: Endocrinology Source Type: research
What to Know About High Triglycerides
Discussions about heart health often center around blood pressure and cholesterol, with factors like poor sleep, smoking, family history of heart disease, and chronic stress thrown in. However, there’s one variable that doesn’t get covered as often, even though it can be an important indicator of cardiovascular risk: triglycerides.
“We don’t really talk about triglycerides very much, especially compared to cholesterol, but they’re actually an essential part of understanding heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health in New York. “For some...
Source: TIME: Health - May 23, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
Efficacy and safety of the use of alirocumab in real clinical practice
CONCLUSION: The inclusion of alirocumab in the treatment regimen contributed to the stable course of atherosclerosis-associated diseases, the achievement of LDL cholesterol targets in 77.8% of patients, was not accompanied by side effects during 2.5 years therapy.PMID:37167185 | DOI:10.26442/00403660.2022.12.201991
Source: Atherosclerosis - May 11, 2023 Category: Cardiology Authors: V A Korneva T Y Kuznetsova I S Scopets N N Vezikova Source Type: research
The 5 Best Ways to Control High Cholesterol, According to People With the Condition
There are a variety of factors that influence cardiovascular risk—but cholesterol is one of the first things that doctors pay attention to.
Having high levels of low-density lipoprotein (LDL) cholesterol is “definitely a variable we try to manage, because it’s been shown to be problematic for heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health.
Though it’s often called the “bad” kind of cholesterol, LDL cholesterol makes up most of your body’s cholesterol stores. That means it’s not a villain on its own, but when levels start creeping ...
Source: TIME: Health - January 18, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort
ConclusionsThe VITAL data confirmed diabetes as an important risk factor for cardiovascular events in a contemporary cohort but did not show cardiovascular benefits of aspirin in primary prevention among people with diabetes who were shown to be at higher risk of cardiovascular events.
Source: Journal of Endocrinological Investigation - January 18, 2023 Category: Endocrinology Source Type: research
Natural products of traditional Chinese medicine treat atherosclerosis by regulating inflammatory and oxidative stress pathways
This study aimed to update and summarize progress in understanding how natural medicines treat AS via inflammatory and oxidative stress-related signaling pathways. We also planned to create an information base for the development of novel drugs for future AS treatment.PMID:36249778 | PMC:PMC9563010 | DOI:10.3389/fphar.2022.997598
Source: Atherosclerosis - October 17, 2022 Category: Cardiology Authors: Tianwei Meng Xinghua Li Chengjia Li Jiawen Liu Hong Chang Nan Jiang Jiarui Li Yabin Zhou Zhiping Liu Source Type: research
Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients
ConclusionThe results of this study showed better population-level effectiveness of simvastatin compared with gemfibrozil for the primary prevention of MACE; however, a definitive randomized controlled trial is required to compare simvastatin with gemfibrozil among patients with low HDL cholesterol, as they appear to obtain benefit with gemfibrozil.
Source: Clinical Drug Investigation - October 14, 2022 Category: Drugs & Pharmacology Source Type: research
Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis
CONCLUSIONS: Among individuals with CAC = 0, the ASCVD PRS was associated with incident ASCVD events. This appears to be driven by genetic variants related to stroke but not CHD, and particularly among women and non-Whites. ASCVD event rates remained below the threshold recommended for consideration for initiation of statin therapy even in the high PRS groups.PMID:35952728 | DOI:10.1016/j.pcad.2022.08.003
Source: Atherosclerosis - August 11, 2022 Category: Cardiology Authors: Mahmoud Al Rifai Jie Yao Xiuqing Guo Wendy S Post Shaista Malik Roger S Blumenthal Christie M Ballantyne Matthew Budoff Kent D Taylor Henry J Lin Stephen S Rich Catherine Hajek Philip Greenland Jerome I Rotter Salim S Virani Source Type: research
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research
